-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Esophageal cancer is a common and poor prognosis cancer
The incidence and death of esophageal cancer in China accounted for nearly half of the world, and esophageal cancer is also the fourth leading cause of cancer death in China
Prevention Lancet
The report shows that China’s burden of esophageal cancer morbidity and death accounts for nearly half of the world’s total, and suggests five major risk factors that are closely related to daily life
The report shows that China’s burden of esophageal cancer morbidity and death accounts for nearly half of the world’s total, and suggests five major risk factors that are closely related to daily life
According to the " Regulations for Diagnosis and Treatment of Esophageal Cancer (2018 Edition)" published by the National Health Commission of China, squamous cell carcinoma is the main type of esophageal cancer in China, accounting for more than 90%
Clinics and esophageal cancer in 2017 is attributable to the five known risk factors, including: smoking (39.
The researchers conducted a randomized, placebo-controlled, double-blind, phase 3 study in 168 medical centers in 26 countries
Between July 25, 2017 and June 3, 2019, 1020 patients were screened, 749 patients were selected, and randomly assigned to K drug plus chemotherapy (n=373[50%]) or placebo plus chemotherapy ( n=376[50%])
The overall survival rate of K drug plus chemotherapy in patients with esophageal squamous cell carcinoma and PD-L1 CPS ≥ 10 is better than placebo plus chemotherapy, and the risk of death is reduced by 43% (median 13.
Different subgroups received OS after pembrolizumab combination
Different subgroups received OS after pembrolizumab combination
In addition, all randomized patients prolonged OS, reduced the risk of death by 27% (12.
In summary, compared with placebo plus chemotherapy, K plus chemotherapy improved the overall survival of previously untreated patients with advanced esophageal squamous cell carcinoma and PD-L1 CPS ≥10, as well as esophageal squamous cell carcinoma and PD-L1 CPS.
references:
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Leave a message here
